Log in
(Ad)
Many traders become obsessed with the big win. But successful trading isn't about hitting home runs, it's about raising your batting average. Rob Booker has the blueprint for steady, reliable account growth, like $100 a day, every day, even with tiny accounts. Do you want to leverage incredible risk/reward ratios in your favor?

NASDAQ:TROV - TrovaGene Stock Price, Forecast & News

$1.72
+0.15 (+9.55 %)
(As of 01/23/2020 07:54 AM ET)
Today's Range
$1.61
Now: $1.72
$1.84
50-Day Range
$1.19
MA: $1.32
$1.72
52-Week Range
$0.88
Now: $1.72
$9.65
Volume1.64 million shs
Average Volume475,826 shs
Market Capitalization$13.31 million
P/E RatioN/A
Dividend YieldN/A
Beta0.17
Trovagene, Inc, a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TROV
CUSIPN/A
Phone858-952-7570

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$380,000.00
Book Value$2.63 per share

Profitability

Net Income$-16,460,000.00
Net Margins-3,797.67%

Miscellaneous

EmployeesN/A
Market Cap$13.31 million
Next Earnings Date3/4/2020 (Estimated)
OptionableOptionable

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

In early 2019 President Trump warned this company's biggest customers to "step up their 5G efforts." A few months later, he banned their biggest competitor from doing business in the U.S. Now, this $5 stock could turn a $10,000 stake into $234,770 this year. But timing is critical. A single mention on the evening news and this opportunity could get away from you.

TrovaGene (NASDAQ:TROV) Frequently Asked Questions

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

When did TrovaGene's stock split? How did TrovaGene's stock split work?

TrovaGene's stock reverse split before market open on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split.

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) issued its earnings results on Thursday, November, 7th. The medical research company reported ($0.71) earnings per share for the quarter, beating analysts' consensus estimates of ($0.84) by $0.13. The medical research company had revenue of $0.05 million for the quarter. TrovaGene had a negative net margin of 3,797.67% and a negative return on equity of 185.18%. View TrovaGene's Earnings History.

When is TrovaGene's next earnings date?

TrovaGene is scheduled to release their next quarterly earnings announcement on Wednesday, March 4th 2020. View Earnings Estimates for TrovaGene.

What price target have analysts set for TROV?

2 equities research analysts have issued 1-year price targets for TrovaGene's stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate TrovaGene's share price to reach $14.50 in the next year. This suggests a possible upside of 743.0% from the stock's current price. View Analyst Price Targets for TrovaGene.

What is the consensus analysts' recommendation for TrovaGene?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for TrovaGene.

What are Wall Street analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:
  • 1. Maxim Group analysts commented, "Trovagene reported 2Q19 with a net loss of ($4.1M) and ended the period with $10.8M in cash on the balance sheet." (8/9/2019)
  • 2. According to Zacks Investment Research, "Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA. Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. " (5/9/2019)

Has TrovaGene been receiving favorable news coverage?

Media coverage about TROV stock has trended somewhat negative on Thursday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TrovaGene earned a news sentiment score of -1.0 on InfoTrie's scale. They also gave press coverage about the medical research company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for TrovaGene.

Who are some of TrovaGene's key competitors?

What other stocks do shareholders of TrovaGene own?

Who are TrovaGene's key executives?

TrovaGene's management team includes the folowing people:
  • Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)
  • Dr. Mark Erlander, Chief Scientific Officer (Age 59)
  • Ms. Elizabeth Anderson, VP of Fin. & Admin.
  • Mr. George Samuel, VP & Gen. Counsel
  • Ms. Vicki Kelemen, VP of Corp. Communications

Who are TrovaGene's major shareholders?

TrovaGene's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Wedbush Securities Inc. (0.33%). Company insiders that own TrovaGene stock include Rodney S Markin and Stanley Tennant. View Institutional Ownership Trends for TrovaGene.

Which major investors are buying TrovaGene stock?

TROV stock was acquired by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought TrovaGene stock in the last two years include Rodney S Markin and Stanley Tennant. View Insider Buying and Selling for TrovaGene.

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $1.72.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $13.31 million and generates $380,000.00 in revenue each year. The medical research company earns $-16,460,000.00 in net income (profit) each year or ($8.26) on an earnings per share basis. View Additional Information About TrovaGene.

What is TrovaGene's official website?

The official website for TrovaGene is http://www.trovagene.com/.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]


MarketBeat Community Rating for TrovaGene (NASDAQ TROV)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  375 (Vote Outperform)
Underperform Votes:  273 (Vote Underperform)
Total Votes:  648
MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote "Outperform" if you believe TROV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Featured Article: What is the S&P/TSX Index?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel